Total Payments
$745,800
2024 Payments
$94,800
Companies
8
Transactions
130
Medicare Patients
2,546
Medicare Billing
$156,873
Payment Breakdown by Category
Research$589,900 (79.1%)
Consulting$153,600 (20.6%)
Other$2,300 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $589,900 | 88 | 79.1% |
| Consulting Fee | $153,600 | 41 | 20.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,300 | 1 | 0.3% |
Payments by Type
Research
$589,900
88 transactions
General
$155,900
42 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $332,200 | 72 | $0 (2024) |
| Eli Lilly and Company | $214,400 | 14 | $0 (2024) |
| PFIZER INC. | $66,200 | 17 | $0 (2023) |
| ARENA PHARMACEUTICALS, INC. | $57,500 | 14 | $0 (2024) |
| Celltrion, Inc. | $43,300 | 2 | $0 (2023) |
| MEDIVATION LLC. | $12,600 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $10,200 | 3 | $0 (2024) |
| Boehringer Ingelheim RCV GmbH & Co KG | $9,400 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $94,800 | 14 | ARENA PHARMACEUTICALS, INC. ($34,100) |
| 2023 | $93,600 | 29 | AbbVie Inc. ($33,900) |
| 2022 | $181,500 | 25 | ABBVIE INC. ($73,000) |
| 2021 | $154,600 | 22 | ABBVIE INC. ($85,000) |
| 2020 | $148,300 | 20 | AbbVie Inc. ($68,600) |
| 2019 | $32,500 | 12 | AbbVie, Inc. ($27,100) |
| 2018 | $34,100 | 6 | AbbVie, Inc. ($33,300) |
| 2017 | $6,400 | 2 | AbbVie, Inc. ($6,400) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/15/2024 | MEDIVATION LLC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $7,200.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 08/15/2024 | MEDIVATION LLC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $5,100.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 08/15/2024 | MEDIVATION LLC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 05/16/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $26,100.00 | Research |
| Study: A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | ||||||
| 05/16/2024 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $10,800.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 05/16/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | ||||||
| 05/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | — | Cash or cash equivalent | $4,900.00 | Research |
| Study: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 05/16/2024 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 05/16/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | ||||||
| 05/16/2024 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 02/16/2024 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $13,200.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 02/16/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $9,300.00 | General |
| 02/16/2024 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 02/16/2024 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/17/2023 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/17/2023 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/17/2023 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/17/2023 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/17/2023 | AbbVie Inc. | SKYRIZI (Biological) | — | Cash or cash equivalent | $100.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 08/15/2023 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 08/15/2023 | Boehringer Ingelheim RCV GmbH & Co KG | SPEVIGO (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2023 | AbbVie Inc. | SKYRIZI (Biological) | — | Cash or cash equivalent | $1,100.00 | Research |
| Study: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis • Category: IMMUNOLOGY | ||||||
| 08/15/2023 | ARENA PHARMACEUTICALS, INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 08/15/2023 | PFIZER INC. | LITFULO (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $72,300 | 3 |
| M14-234 | AbbVie, Inc. | $60,900 | 10 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $58,700 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $57,000 | 4 |
| CT-P13 3.7 | Celltrion, Inc. | $43,300 | 2 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | ABBVIE INC. | $41,700 | 6 |
| M14-234 | AbbVie Inc. | $30,100 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $25,300 | 2 |
| A PHASE 3 MULTICENTER OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $18,000 | 1 |
| M14-675 | AbbVie Inc. | $17,800 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $16,500 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy | ABBVIE INC. | $15,900 | 3 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | AbbVie Inc. | $14,200 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis | AbbVie Inc. | $13,100 | 3 |
| A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | ABBVIE INC. | $12,900 | 2 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 | ABBVIE INC. | $9,300 | 4 |
| A Study of the Efficacy and Safety of Risankizumab in Participants With Crohns Disease | ABBVIE INC. | $9,000 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $8,300 | 1 |
| M16-067 | AbbVie Inc. | $7,500 | 2 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 | AbbVie Inc. | $6,600 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease Who Failed Prior Biologic Treatment | ABBVIE INC. | $6,300 | 2 |
| M14-431 | AbbVie Inc. | $6,000 | 2 |
| AN ADAPTIVE PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LY3471851 (NKTR 358) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $5,900 | 1 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | ABBVIE INC. | $5,000 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohns Disease Who Have Inadequately Responded to or are Intolerant to Conventional and/or Biologic Therapies | ABBVIE INC. | $4,800 | 2 |
| M14-675 | AbbVie, Inc. | $4,500 | 2 |
| M15-991 | AbbVie Inc. | $3,900 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 | ABBVIE INC. | $3,300 | 2 |
| M14-433 | AbbVie Inc. | $3,300 | 2 |
| A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | ABBVIE INC. | $2,400 | 2 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis | ABBVIE INC. | $2,200 | 3 |
| A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PARALLEL PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $2,200 | 1 |
| M14-431 | AbbVie, Inc. | $1,400 | 2 |
| A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PARALLEL-ARM PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 591 | 1,209 | $174,559 | $34,335 |
| 2022 | 12 | 702 | 1,384 | $204,215 | $38,470 |
| 2021 | 12 | 664 | 1,318 | $207,707 | $44,003 |
| 2020 | 10 | 589 | 1,279 | $185,048 | $40,065 |
Total Patients
2,546
Total Services
5,190
Medicare Billing
$156,873
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 296 | 640 | $90,880 | $17,004 | 18.7% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 64 | 250 | $22,000 | $5,388 | 24.5% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 110 | 142 | $22,862 | $3,772 | 16.5% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2023 | 13 | 29 | $15,573 | $3,198 | 20.5% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2023 | 25 | 34 | $10,438 | $2,101 | 20.1% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2023 | 24 | 36 | $5,292 | $1,146 | 21.7% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2023 | 14 | 20 | $3,220 | $944.61 | 29.3% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2023 | 16 | 24 | $2,424 | $486.23 | 20.1% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2023 | 29 | 34 | $1,870 | $294.42 | 15.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 367 | 790 | $112,180 | $20,034 | 17.9% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2022 | 59 | 227 | $21,083 | $4,878 | 23.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 124 | 155 | $24,955 | $4,082 | 16.4% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2022 | 20 | 32 | $17,184 | $3,443 | 20.0% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 33 | 46 | $14,122 | $2,919 | 20.7% |
| 88323 | Surgical pathology consultation and report on referred material requiring preparation of slides | Facility | 2022 | 11 | 11 | $3,729 | $756.54 | 20.3% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2022 | 15 | 21 | $3,087 | $688.30 | 22.3% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2022 | 11 | 11 | $2,321 | $595.58 | 25.7% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2022 | 16 | 26 | $2,626 | $540.53 | 20.6% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2022 | 14 | 27 | $1,215 | $241.89 | 19.9% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2022 | 19 | 25 | $1,375 | $223.88 | 16.3% |
| 88302 | Pathology examination of tissue using a microscope | Facility | 2022 | 13 | 13 | $338.00 | $66.26 | 19.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2021 | 289 | 586 | $83,212 | $16,922 | 20.3% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2021 | 24 | 57 | $30,609 | $6,522 | 21.3% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2021 | 56 | 266 | $23,408 | $6,032 | 25.8% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2021 | 49 | 82 | $25,174 | $5,295 | 21.0% |
About Reetesh Pai
Reetesh Pai is a Anatomic Pathology & Clinical Pathology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1962608364.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Reetesh Pai has received a total of $745,800 in payments from pharmaceutical and medical device companies, with $94,800 received in 2024. These payments were reported across 130 transactions from 8 companies. The most common payment nature is "" ($589,900).
As a Medicare-enrolled provider, Pai has provided services to 2,546 Medicare beneficiaries, totaling 5,190 services with total Medicare billing of $156,873. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Anatomic Pathology & Clinical Pathology
- Location Palo Alto, CA
- Active Since 06/22/2007
- Last Updated 05/24/2021
- Taxonomy Code 207ZP0102X
- Entity Type Individual
- NPI Number 1962608364
Products in Payments
- SKYRIZI (Biological) $106,200
- RINVOQ (Biological) $99,600
- VELSIPITY (Drug) $70,100
- RINVOQ (Drug) $57,200
- Rinvoq (Biological) $12,900
- SPEVIGO (Drug) $3,900
- LITFULO (Drug) $3,600
- HUMIRA (Biological) $2,400
- Pipeline (Drug) $2,300
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology & Clinical Pathology Doctors in Palo Alto
Susan Galel, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $77,135
Anatomic Pathology & Clinical Pathology $77,135
Dr. Karen Johnston, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $401.37
Anatomic Pathology & Clinical Pathology $401.37
Jon Keller, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $149.70
Anatomic Pathology & Clinical Pathology $149.70
Puneeta Sarma Vasa
Anatomic Pathology & Clinical Pathology — Payments: $137.99
Anatomic Pathology & Clinical Pathology $137.99
Elise Rosen-Levin, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $101.29
Anatomic Pathology & Clinical Pathology $101.29
Melissa Clark, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $83.00
Anatomic Pathology & Clinical Pathology $83.00